Sarcomas, a rare and aggressive category of over 100 connective tissue malignancies, present a significant challenge due to high metastasis rates and resistance to standard therapies like conventional chemotherapy and first-generation checkpoint inhibitors.
A major breakthrough is occurring with Adoptive Cell Therapy (ACT), where a patient’s immune cells are genetically engineered to target cancer. Notably, the TCR-T cell therapy afamitresgene autoleucel (afami-cel), which targets MAGE-A4, achieved a 39% response rate in metastatic synovial sarcoma, resulting in the first FDA approval for an engineered T-cell therapy in a solid tumor. Similar success was seen with the NY-ESO-1 targeting therapy, lete-cel. Furthermore, CAR-NK cells are being developed as a promising, antigen-independent strategy, capitalizing on the high sensitivity of sarcomas to NK-mediated killing.
To fully realize the potential of ACT, several obstacles must be overcome: identifying shared, tumor-specific antigens using advanced methods like immunopeptidomics; overcoming the highly immunosuppressive tumor microenvironment (TME) to improve cell persistence and trafficking; optimizing manufacturing using AI and developing “off-the-shelf” allogeneic products; and administering the therapy strategically at a low-disease burden state, where efficacy is proven to be highest.